Literature DB >> 17565922

Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis.

Tuncay Delibasi1, Rifat Emral, Murat F Erdogan, Nuri Kamel.   

Abstract

Osteoporosis and cardiovascular disease are major health problems that lead to morbidity and mortality. Bisphosphonates are among the drugs used most frequently worldwide to treat osteoporosis, especially in older women. B-mode ultrasonography has recently become a valuable tool for early diagnosis of atherosclerotic disease because of its ability to measure carotid artery intima media thickness (CIMT). The purpose of the present study was to investigate whether alendronate sodium therapy has an effect on CIMT in postmenopausal women with osteoporosis. A total of 71 postmenopausal women with osteoporosis were evaluated before and after they began taking alendronate sodium; follow-up was provided for an average of 13+/-2 mo. Osteoporosis was diagnosed with the use of dual-energy x-ray absorptiometry, and therapy with alendronate sodium was begun at a dose of 70 mg/wk. For CIMT, B-mode ultrasonography was performed on the right and left middle and distal main carotid arteries. Before alendronate sodium therapy was initiated, the average CIMT value was 0.734+/-0.121 mm; after therapy, the average CIMT was 0.712+/-0.111 mm. This difference was not confirmed to be statistically significant. Treatment of osteoporosis does not seem to have an effect on CIMT, which is an early marker of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565922     DOI: 10.1007/BF02849900

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  7 in total

1.  A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke.

Authors:  J-H Kang; J J Keller; H-C Lin
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

2.  Therapeutic perspectives.

Authors:  Carmelo E Fiore; Pietra Pennisi; Marianna Tinè
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

3.  Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study.

Authors:  J-H Kang; J J Keller; H-C Lin
Journal:  Osteoporos Int       Date:  2012-11-14       Impact factor: 4.507

4.  Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study.

Authors:  C-K Chen; H-T Chang; H-P Chou; M-H Lee; Y-C Chen; Y-C Huang; T-J Chen; H-L Chang; C-C Shih
Journal:  Osteoporos Int       Date:  2013-08-14       Impact factor: 4.507

5.  Do bisphosphonates and RANKL inhibitors alter the progression of coronary artery calcification? A systematic review and meta-analysis protocol.

Authors:  Samantha Louise Saunders; Nathan Scott McOrist; Kanika Chaudhri; Sonali R Gnanenthiran; Grant Shalaby
Journal:  BMJ Open       Date:  2022-10-07       Impact factor: 3.006

6.  Vascular effects of bisphosphonates-a systematic review.

Authors:  Leyna L Santos; Taciana B Cavalcanti; Francisco A Bandeira
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2012-10-25

Review 7.  Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.

Authors:  Carla Caffarelli; Andrea Montagnani; Ranuccio Nuti; Stefano Gonnelli
Journal:  Clin Interv Aging       Date:  2017-10-30       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.